Innovent Biologics (HK:1801) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Innovent Biologics, Inc. has announced its current Board of Directors, comprised of executive and independent non-executive members, including Dr. De-Chao Michael Yu as Chairman and CEO. The company also outlined the composition of its four Board committees – Audit, Remuneration, Nomination, and Strategy – detailing the roles and chairmanships held by various directors.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
